| pubmed-article:16585018 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C0074554 | lld:lifeskim |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C1442989 | lld:lifeskim |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:16585018 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:16585018 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16585018 | pubmed:dateCreated | 2006-4-4 | lld:pubmed |
| pubmed-article:16585018 | pubmed:abstractText | In vitro statins induce apoptosis in myeloma and lymphoma cells in a dose-and time-dependent way. In combination with dexamethasone and doxorubicin, statins have a chemo-sensitizing effect. Twenty-eight patients with relapsed myeloma or lymphoma were treated with a dose-escalating regimen of simvastatin for 7 days followed by VAD in myeloma patients and CHOP in lymphoma patients. The maximum tolerated dose was 15 mg/kg/day simvastatin. The most frequently reported side-effects were fatigue, gastrointestinal CTC grade 1-2 and neutropenic fever. The dose-limiting toxicity was neutropenic sepsis and grade 3 gastrointestinal side effects. High-dose simvastatin given immediately prior to chemotherapy is safe and tolerable up to a dose of 15 mg/kg/day. | lld:pubmed |
| pubmed-article:16585018 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16585018 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16585018 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16585018 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16585018 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16585018 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:16585018 | pubmed:issn | 1592-8721 | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:WittebolShula... | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:BloemAndries... | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:LokhorstHenk... | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:van de... | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:BogersLijnie... | lld:pubmed |
| pubmed-article:16585018 | pubmed:author | pubmed-author:KramerMark... | lld:pubmed |
| pubmed-article:16585018 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:16585018 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:16585018 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16585018 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16585018 | pubmed:pagination | 542-5 | lld:pubmed |
| pubmed-article:16585018 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:meshHeading | pubmed-meshheading:16585018... | lld:pubmed |
| pubmed-article:16585018 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16585018 | pubmed:articleTitle | Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. | lld:pubmed |
| pubmed-article:16585018 | pubmed:affiliation | Department of Hematology and Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands. | lld:pubmed |
| pubmed-article:16585018 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16585018 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16585018 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16585018 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16585018 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16585018 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16585018 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16585018 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16585018 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16585018 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16585018 | lld:pubmed |
